{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:01:00Z","timestamp":1740153660305,"version":"3.37.3"},"reference-count":20,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Bristol Myers Squibb"},{"name":"Boehringer-Ingelheim"},{"name":"Astra-Zeneca"},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.2217\/imt-2017-0144","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T11:32:24Z","timestamp":1513769544000},"page":"77-80","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy in Relapsed Mesothelioma"],"prefix":"10.1080","volume":"10","author":[{"given":"Solenn","family":"Brosseau","sequence":"first","affiliation":[{"name":"Thoracic Oncology Department & Early Trial Clinical Research Center, Hospital Bichat-Claude Bernard, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), F-75018Paris, France"},{"name":"University Paris-Diderot, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Dhalluin","sequence":"additional","affiliation":[{"name":"Pulmonary & Thoracic Oncology, Univ Lille, CHU Lille, INSERM U1019, CIIL, Institut Pasteur de Lille, F59000Lille, France"},{"name":"French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN), Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Zalcman","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department & Early Trial Clinical Research Center, Hospital Bichat-Claude Bernard, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), F-75018Paris, France"},{"name":"University Paris-Diderot, Paris, France"},{"name":"U830 Inserm, \u2018Genetics & Biology of Cancers\u2019, Research Center-Institut Curie"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[{"name":"Pulmonary & Thoracic Oncology, Univ Lille, CHU Lille, INSERM U1019, CIIL, Institut Pasteur de Lille, F59000Lille, France"},{"name":"French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN), Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00063109"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv199"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.03.006"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.013"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.018"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.033"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.01.010"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Kindler H KarrisonT TanYHCet al. Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis . WCLC abstract OA13.02 ( 2016 ).","DOI":"10.1016\/j.jtho.2016.11.301"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Quispel-Janssen J ZimmermannM BuikhuisenS BurgersG BaasP . A phase II study of nivolumab in malignant pleural mesothelioma NivoMes): with translational research (TR) biopsies . WCLC abstract OA13.01 ( 2016 ).","DOI":"10.1016\/j.jtho.2016.11.300"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.8503"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Scherpereel A Mazi\u00e8resJ GreillerLet al. Second or third-line nivolumab versus nivolumab plus ipilimumab in malignant pleural mesothelioma patients: results of the IFCT-1501 MAPS-2 randomized phase 3 trial . ASCO abstract LBA8507 ( 2017 ).","DOI":"10.1200\/JCO.2017.35.15_suppl.LBA8507"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Zalcman G MazieresJ GreillerLet al. Second or 3rd line nivolumab (nivo) or nivo plus ipilimumab in malignant pleural mesothelioma (MPM) patients: up-dated results of the IFCT-1501 MAPS1 randomized phase 2 trial . ESMO abstract LBA58_PR ( 2017 ).","DOI":"10.1093\/annonc\/mdx440.074"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Mauti LA KlingbielD SchmidSet al. Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma; a Swiss registry . ESMO abstract 1615O ( 2017 ).","DOI":"10.1093\/annonc\/mdx389"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Calabro L MorraA GiannarelliDet al. Tremelimumab plus Durvalumab in first-or secondline mesothelioma patients: final analysis of the NIBIT-MESO-1 Study . WCLC abstract 9202 ( 2017 ).","DOI":"10.1016\/j.jtho.2017.09.635"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2017-0144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:13:39Z","timestamp":1715958819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2017-0144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.2217\/imt-2017-0144"],"URL":"https:\/\/doi.org\/10.2217\/imt-2017-0144","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"type":"print","value":"1750-743X"},{"type":"electronic","value":"1750-7448"}],"subject":[],"published":{"date-parts":[[2017,12,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}